From Genomics to Practice Part II: Personalised Healthcare from the Perspective of Genomic Information
- Begins:
- 4.10.2024
- Credits:
- 0
- Location:
- Kuopio
- Continuous learning category:
- Social welfare and health care
- Teaching format:
- Contact teaching, Distance teaching
- Price:
- 0 € (VAT 0%)
Join us for a training session where experts in the field will share knowledge and practical examples of how genome data can be used. In the morning seminar, you will learn how genomic data can provide an opportunity for personalised medicine applications, how genetic testing for brain diseases is being developed, and the potential of the FinnGen project and the Finnish biobanking system for patient selection in clinical trials.
Afternoon workshop provides you an inspiring opportunity to innovate the most efficient way to use genetic data in your company based on the introductory speeches heard in the morning session.
Make the most of the training day and expand your network by getting to know other participants during breaks and the workshop.
Sign up for the training day by 23.9.2024, (For a more detailed program of the day, see the bottom of the page)
Attendance and language:
You can attend the seminars on-site in Kuopio or remotely via Teams. The workshop in the afternoon will only be arranged via Teams.
The training session and materials are in English. You can join the discussion in English or in Finnish.
The training has been organised in cooperation with the ReguVa project, the UEF Brain Research Unit 2.0 ERDF project (UEF ATY 2.0) and the Genome Center of Eastern Finland.
The “From Genomics to Practice Part II” training day is a follow-up to the “From Genomics to Practice Part I” training day held earlier this spring
After this training, the participant will be able to
- identify the potential uses of genomic information.
- provide examples of patient groups that can be identified using genomic data and that will benefit from new clinical therapies
- provide examples of the potential of genomic information for applications of personalised medicine to improve the diagnosis, treatment and prevention of diseases
- describe the potential of FinnGen and biobanks to enhance clinical research.
In the workshop participants will innovate advantageous ways to use genomic information in their own organization.
Professionals working in pharmaceutical, health technology and other healthcare companies, research organisations or in wellbeing service counties. Well suited for those working in product development and research, clinical trials and education. The event, especially the workshop, is intended for companies from start-ups and health tech to pharma.
Friday 4.10.2024 at 10-15:30
Location: University of Eastern Finland, Tietoteknia building, seminar class 1037 (Savilahdentie 6, 70210 Kuopio).
You can attend the event on-site in Kuopio or remotely via Teams.
We will inform you of any changes.
Free training.
The ReguVa project is co-funded by the European Union.
The UEF ATY 2.0 project is co-funded by the European Union (European Regional Development Fund (ERDF), the Regional Council of Pohjois-Savo).
PROGRAM OF THE DAY
9:40 – 10:00 Registration
10:00 – 10:15 Opening of the day – the importance of the co-operation for the benefit of clients and patients
Chair of the session Mikko Hiltunen, Professor, Institute of Biomedicine, UEF
10:15 – 10:40 Case 1 – High-quality genetic analysis services at the Genome Center of Eastern Finland
Jaana Hartikainen, Research Manager, Institute of Clinical Medicine,
- What genome information can be used for?
- How Genome Center of Eastern Finland is involved in diagnostics, product development and research - Example: cancer diagnostics
10:40 – 11:05 Case 2 - Development and utilization of genetic screening for brain diseases in the Brain Research Unit 2.0 ERDF project
Mikko Hiltunen, Professor, Institute of Biomedicine, UEF
- How to identify individuals at increased genetic risk from biobank cohorts
- To understand how genetic information offers opportunities for personalized medicine applications that can improve the diagnosis, treatment, and prevention of diseases
11:05 – 11:30 Case 3 - FinnGen and the Finnish biobank system as a platform for enhanced patient selection
Valtteri Julkunen, Clinical Lecturer, Institute of Clinical Medicine, UEF
- How does FinnGen serve not only as a platform for genetic research but also for new clinical trials?
- What opportunities does the biobank system create for targeted patient selection and how does it enhance patient selection for clinical trials and drug development?
11:30 – 11:45 RNatives platform technology: From genomic information to novel RNA therapeutics
Mikko Turunen, PhD Biotechnology, Chief Scientific Officer, RNatives Inc
11:45 – 12:30 Lunch (We kindly request attendees to cover their meal expenses)
12:30 – 13:30 Workshop: Use of genetic information in medical research and development - Tailored services and closer co-operation for the patients' best interests.
Facilitator: Sanna Soppela, Continuous Learning Specialist, Continuous
Learning Center, UEF
13:30 – 14:00 Coffee break
14:00 – 15:20 Workshop continues
15:20 – 15:30 Summary and conclusion of the day
Mikko Hiltunen, Professor, Institute of Biomedicine, UEF
In cooperation
Instructor
Mikko Hiltunen
Professor
Institute of Biomedicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland
Mikko Hiltunen, professor of tissue and cell biology at the University of Eastern Finland, works, in addition to the teaching and research work at the Institute of Biomedicine, as the director of the neuroscience research community (NEURO-RC), the Genome Center of Eastern Finland, and the Alzheimer's disease molecular genetics research group. Professor Hiltunen has played a central role in recent genetic studies of Alzheimer's disease, in which dozens of new risk-increasing and protective gene variants have been identified. He is a member of the management team of the European EADB (A European DNA bank for deciphering the missing heritability of Alzheimer's disease) project and leads the FIRI infrastructure project funded by the Academy of Finland, where the focus is on strengthening genetics and genomics expertise at the University of Eastern Finland. He also acts as the responsible manager of the "UEF Brain Research Unit 2.0" ERDF project and actively participates in the activities of the Neuro-Innovation research school (MSCA Horizon 2020 PhD programme).
Valtteri Julkunen
Clinical Lecturer, Neurologist, MD, PhD
Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland
Valtteri Julkunen works as a Clinical Lecturer of the subject of neurology at the University of Eastern Finland, a specialist in neurology at Kuopio University Hospital, and a clinical researcher at the University of Eastern Finland and in the FinnGen research project coordinated by the University of Helsinki. His research work focuses on the development of diagnostic methods for neurodegenerative diseases and especially Alzheimer's disease. In recent years, Julkunen has worked as the medical director and corresponding researcher of the extensive biobank research (TWINGEN) funded by FinnGen. This research project aims to develop clinical recall studies carried out with biobanks and biomarkers related to the identification of the early stage of Alzheimer's disease.
Jaana Hartikainen
Research Manager, PhD, Docent
Institute of Clinical Medicine, School of Medicine, Faculty of Health Sciences, University of Eastern Finland
Research Manager Jaana Hartikainen works at the University of Eastern Finland in the Institute of Clinical Medicine. Hartikainen leads the method development and service activities related to cancer diagnostics and research in the Gene Diagnostics Laboratory of the Genome Center of Eastern Finland. In addition, she is involved in the Cancer Research Group of Clinical Pathology and Forensic Medicine and belongs to the UEF’s CANCER Research Community (RC). Her research interests are focused on breast and gynecological cancers, their heredity, heritability, cancer risk and molecular characteristics of tumors. Hartikainen is an expert member of Kuopio University Hospital's multidisciplinary gene-directed cancer treatment working group (Molecular Tumor Board).
Mikko Turunen
PhD, Docent of Molecular Medicine
University of Eastern Finland
Mikko Turunen is the founder and CSO of RNatives Inc. He has +27 years of experience in the development of gene therapies. Throughout his career, his research focus has been non-coding RNAs, cardiovascular disease, and gene delivery to animals. He was the first to show transcriptional gene activation by small RNAs in vivo (2009). In addition to work carried out at UEF, he has worked at Ark Therapeutics, University of Torino, Italy and The Scripps Research Institute, San Diego, USA.
Planner
Share
